Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.

Urinary expressed prostatic secretion or "EPS-urine" is proximal tissue fluid that is collected after a digital rectal exam (DRE). EPS-urine is a rich source of prostate-derived proteins that can be used for biomarker discovery for prostate cancer (PCa) and other prostatic diseases. We previously conducted a comprehensive proteome analysis of direct expressed prostatic secretions (EPS). In the current study, we defined the proteome of EPS-urine employing Multidimensional Protein Identification Technology (MudPIT) and providing a comprehensive catalogue of this body fluid for future biomarker studies. We identified 1022 unique proteins in a heterogeneous cohort of 11 EPS-urines derived from biopsy negative noncancer diagnoses with some benign prostatic diseases (BPH) and low-grade PCa, representative of secreted prostate and immune system-derived proteins in a urine background. We further applied MudPIT-based proteomics to generate and compare the differential proteome from a subset of pooled urines (pre-DRE) and EPS-urines (post-DRE) from noncancer and PCa patients. The direct proteomic comparison of these highly controlled patient sample pools enabled us to define a list of prostate-enriched proteins detectable in EPS-urine and distinguishable from a complex urine protein background. A combinatorial analysis of both proteomics data sets and systematic integration with publicly available proteomics data of related body fluids, human tissue transcriptomic data, and immunohistochemistry images from the Human Protein Atlas database allowed us to demarcate a robust panel of 49 prostate-derived proteins in EPS-urine. Finally, we validated the expression of seven of these proteins using Western blotting, supporting the likelihood that they originate from the prostate. The definition of these prostatic proteins in EPS-urine samples provides a reference for future investigations for prostatic-disease biomarker studies.

[1]  P. Boutros,et al.  In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. , 2011, Journal of proteome research.

[2]  Nathalie Selevsek,et al.  Toward a standardized urine proteome analysis methodology , 2011, Proteomics.

[3]  T. Conrads,et al.  Advances in proximal fluid proteomics for disease biomarker discovery. , 2010, Journal of proteome research.

[4]  KyungMann Kim,et al.  TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. , 2010, The American journal of pathology.

[5]  A. Ignatchenko,et al.  In-depth proteomic analyses of direct expressed prostatic secretions. , 2010, Journal of proteome research.

[6]  R. Eeles,et al.  The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic target , 2010, The Prostate.

[7]  E. Lundberg,et al.  A global view of protein expression in human cells, tissues, and organs , 2009, Molecular systems biology.

[8]  Jon W. Huss,et al.  BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources , 2009, Genome Biology.

[9]  Baris E. Suzek,et al.  The Universal Protein Resource (UniProt) in 2010 , 2009, Nucleic Acids Res..

[10]  T. Kislinger,et al.  Peptide separations by on-line MudPIT compared to isoelectric focusing in an off-gel format: application to a membrane-enriched fraction from C2C12 mouse skeletal muscle cells. , 2009, Journal of proteome research.

[11]  M. Clements,et al.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. , 2009, Journal of proteomics.

[12]  A. Ignatchenko,et al.  Comparative systems biology of human and mouse as a tool to guide the modeling of human placental pathology , 2009, Molecular systems biology.

[13]  M. Moran,et al.  Automated 2D peptide separation on a 1D nano-LC-MS system. , 2009, Journal of proteome research.

[14]  Hyungwon Choi,et al.  Significance Analysis of Spectral Count Data in Label-free Shotgun Proteomics*S , 2008, Molecular & Cellular Proteomics.

[15]  Igor Jurisica,et al.  Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). , 2008, Molecular bioSystems.

[16]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[17]  Laura Beretta,et al.  Proteomics from the clinical perspective: many hopes and much debate , 2007, Nature Methods.

[18]  Visith Thongboonkerd,et al.  Practical points in urinary proteomics. , 2007, Journal of proteome research.

[19]  Igor Jurisica,et al.  Integrated proteomic and transcriptomic profiling of mouse lung development and Nmyc target genes , 2022 .

[20]  J Alfred Witjes,et al.  The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance , 2007, Clinical Cancer Research.

[21]  M. Mann,et al.  The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins , 2006, Genome Biology.

[22]  N. Maitland,et al.  Prostate cancer stem cells. , 2006, European journal of cancer.

[23]  Michelle S. Scott,et al.  Global Survey of Organ and Organelle Protein Expression in Mouse: Combined Proteomic and Transcriptomic Profiling , 2006, Cell.

[24]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[25]  S. Srivastava,et al.  Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. , 2005, Endocrine-related cancer.

[26]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[27]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[28]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[29]  A. van Dalen,et al.  Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.

[30]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[31]  D. Chan,et al.  Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. , 2001, Urology.

[32]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[33]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[34]  H. Klocker,et al.  Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. , 1998, Urology.

[35]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[36]  María Martín,et al.  The Universal Protein Resource (UniProt) in 2010 , 2010 .

[37]  M. Bissell.  A First-Generation Multiplex Biomarker Analysis of Urine For The Early Detection of Prostate Cancer , 2009 .

[38]  A. Ignatchenko,et al.  A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. , 2008, Journal of proteome research.

[39]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.